Literature DB >> 24550343

A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Anne F Voor In 't Holt1, Juliëtte A Severin, Emmanuel M E H Lesaffre, Margreet C Vos.   

Abstract

A systematic review and meta-analyses were performed to identify the risk factors associated with carbapenem-resistant Pseudomonas aeruginosa and to identify sources and reservoirs for the pathogen. A systematic search of PubMed and Embase databases from 1 January 1987 until 27 January 2012 identified 1,662 articles, 53 of which were included in a systematic review and 38 in a random-effects meta-analysis study. The use of carbapenem, use of fluoroquinolones, use of vancomycin, use of other antibiotics, having medical devices, intensive care unit (ICU) admission, having underlying diseases, patient characteristics, and length of hospital stay were significant risk factors in multivariate analyses. The meta-analyses showed that carbapenem use (odds ratio [OR] = 7.09; 95% confidence interval [CI] = 5.43 to 9.25) and medical devices (OR = 5.11; 95% CI = 3.55 to 7.37) generated the highest pooled estimates. Cumulative meta-analyses showed that the pooled estimate of carbapenem use was stable and that the pooled estimate of the risk factor "having medical devices" increased with time. We conclude that our results highlight the importance of antibiotic stewardship and the thoughtful use of medical devices in helping prevent outbreaks of carbapenem-resistant P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24550343      PMCID: PMC3993224          DOI: 10.1128/AAC.01758-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  106 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  J Clin Epidemiol       Date:  2008-04       Impact factor: 6.437

2.  Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis.

Authors:  M R Mueller; M K Hayden; S K Fridkin; D K Warren; L Phillips; K Lolans; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

3.  Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design.

Authors:  Susy Hota; Zahir Hirji; Karen Stockton; Camille Lemieux; Helen Dedier; Gideon Wolfaardt; Michael A Gardam
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

4.  Molecular epidemiology of outbreaks and containment of drug-resistant Pseudomonas aeruginosa in a Tokyo hospital.

Authors:  Jun-ichiro Sekiguchi; Katsuji Teruya; Kumi Horii; Emi Kuroda; Hisami Konosaki; Yukie Mizuguchi; Minako Araake; Akihiko Kawana; Hiroshi Yoshikura; Tadatoshi Kuratsuji; Hisayoshi Miyazaki; Teruo Kirikae
Journal:  J Infect Chemother       Date:  2007-12-25       Impact factor: 2.211

5.  Controlling the clonal spread of Pseudomonas aeruginosa infection.

Authors:  Graziella H Pereira; Anna S Levin; Helenice Bosco Oliveira; Maria Luiza Moretti
Journal:  Infect Control Hosp Epidemiol       Date:  2008-06       Impact factor: 3.254

Review 6.  Clinically significant carbapenemases: an update.

Authors:  Timothy R Walsh
Journal:  Curr Opin Infect Dis       Date:  2008-08       Impact factor: 4.915

7.  Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates.

Authors:  Thomas P Lodise; Chris Miller; Nimish Patel; Jeffrey Graves; Louise-Anne McNutt
Journal:  Infect Control Hosp Epidemiol       Date:  2007-06-22       Impact factor: 3.254

8.  Nosocomial colonization due to imipenem-resistant Pseudomonas aeruginosa epidemiologically linked to breast milk feeding in a neonatal intensive care unit.

Authors:  Caterina Mammina; Paola Di Carlo; Domenico Cipolla; Alessandra Casuccio; Matilde Tantillo; Maria Rosa Anna Plano; Angela Mazzola; Giovanni Corsello
Journal:  Acta Pharmacol Sin       Date:  2008-12       Impact factor: 6.150

9.  Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa.

Authors:  Spyros D Mentzelopoulos; Maria Pratikaki; Evangelia Platsouka; Helen Kraniotaki; Dimitris Zervakis; Antonia Koutsoukou; Serafim Nanas; Olga Paniara; Charis Roussos; Evangelos Giamarellos-Bourboulis; Christina Routsi; Spyros G Zakynthinos
Journal:  Intensive Care Med       Date:  2007-06-05       Impact factor: 17.440

10.  Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.

Authors:  Pinar Onguru; Ayse Erbay; Hurrem Bodur; Gulseren Baran; Esragul Akinci; Neriman Balaban; Mustafa Aydin Cevik
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

View more
  31 in total

1.  Iminoguanidines as Allosteric Inhibitors of the Iron-Regulated Heme Oxygenase (HemO) of Pseudomonas aeruginosa.

Authors:  Geoffrey A Heinzl; Weiliang Huang; Wenbo Yu; Bennett J Giardina; Yue Zhou; Alexander D MacKerell; Angela Wilks; Fengtian Xue
Journal:  J Med Chem       Date:  2016-07-11       Impact factor: 7.446

2.  Triethysilyl Enol Ethers in the Synthesis of Carbapenem Precursors.

Authors:  Thu Q Nguyen; Weirui Chai; Jane Gu; Katie Cook; Eugene Kim; Sam Goetz; Zach Farni; Monica Chepuru; Melina Cox; Pauline Nguyen; Hashim Raja; Patrick Magistrado; Faith Michael; Peter Oelschlaeger; John D Buynak
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units.

Authors:  Yamin Zou; Jiangping Lian; Ying Di; Haisheng You; Hongping Yao; Junhui Liu; Yalin Dong
Journal:  Int J Clin Pharm       Date:  2017-11-14

4.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.

Authors:  Sara Y Tartof; Jennifer L Kuntz; Lie H Chen; Rong Wei; Laura Puzniak; Yun Tian; Theresa M Im; Harpreet S Takhar; Sanjay Merchant; Thomas Lodise
Journal:  JAMA Netw Open       Date:  2018-10-05

7.  Similar frequencies of Pseudomonas aeruginosa isolates producing KPC and VIM carbapenemases in diverse genetic clones at tertiary-care hospitals in Medellín, Colombia.

Authors:  Johanna M Vanegas; Astrid V Cienfuegos; Ana M Ocampo; Lucelly López; Helena del Corral; Gustavo Roncancio; Patricia Sierra; Lina Echeverri-Toro; Sigifredo Ospina; Natalia Maldonado; Carlos Robledo; Andrea Restrepo; J Natalia Jiménez
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

8.  Antimicrobial resistance and putative virulence genes of Pseudomonas aeruginosa isolates from patients with respiratory tract infection.

Authors:  Heba Y Al Dawodeyah; Nathir Obeidat; Luay F Abu-Qatouseh; Asem A Shehabi
Journal:  Germs       Date:  2018-03-03

Review 9.  In-Hospital Macro-, Meso-, and Micro-Drivers and Interventions for Antibiotic Use and Resistance: A Rapid Evidence Synthesis of Data from Canada and Other OECD Countries.

Authors:  Rosa Stalteri Mastrangelo; Anisa Hajizadeh; Thomas Piggott; Mark Loeb; Michael Wilson; Luis Enrique Colunga Lozano; Yetiani Roldan; Hussein El-Khechen; Anna Miroshnychenko; Priya Thomas; Holger J Schünemann; Robby Nieuwlaat
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-03-16       Impact factor: 2.585

Review 10.  Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.

Authors:  Kathleen Tompkins; David van Duin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-06-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.